Therapy of acute respiratory viral infections in adults in outpatient clinical practice: new opportunities for the prevention of bacterial complications (Results of the observational program RAPORT)
- Authors: Yakovlev S.V.1,2, Dvoretskiy L.I.1, Petrov V.A.3
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Interregional Public Organization "Alliance of Clinical Chemotherapists and Microbiologists"
- Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University MEPhI
- Issue: Vol 25, No 3 (2023): Otorhinolaryngology and pulmonology
- Pages: 157-162
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/131646
- DOI: https://doi.org/10.26442/20751753.2023.3.202166
- ID: 131646
Cite item
Full Text
Abstract
The frequency of routine prescription of systemic antibacterial drugs in outpatient practice is still unreasonably high despite the desire to reduce them. Under the auspices of the Alliance of Clinical Chemotherapists and Microbiologists, the observational program RAPORT was conducted to assess the therapeutic potential (including bacterial complications preventing) of Raphamin in routine clinical practice in adults with acute respiratory viral infection (ARVI). The program included 14,033 patients aged 18–97 years with ARVI who received an investigational drug (ID) as monotherapy (93%) or in combination with basic therapy (7%). The frequency of prophylactic prescribing antibacterial drugs was 0.6%. It was shown that fever duration was 2.31±1.38 days, and the duration of the disease – 3.6±1.52 days. In 99.4% of patients, ID allowed to avoid the development of bacterial complications and prescription of antibacterial drugs. ID showed a stable therapeutic effect – in patients who started treatment late, as well as in patients with a moderate course of ARVI, there was no delay in recovery. The results obtained a broad prospect for the use of ID in order to minimize the number of bacterial complications and the frequency of use of antibiotics in ARVI, which may reduce rate of resistance of topical pathogens in the future.
Full Text
##article.viewOnOriginalSite##About the authors
Sergey V. Yakovlev
Sechenov First Moscow State Medical University (Sechenov University); Interregional Public Organization "Alliance of Clinical Chemotherapists and Microbiologists"
Author for correspondence.
Email: antimicrob@yandex.ru
ORCID iD: 0000-0001-7606-8608
D. Sci. (Med.), Sechenov First Moscow State Medical University (Sechenov University); Interregional Public Organization "Alliance of Clinical Chemotherapists and Microbiologists"
Russian Federation, Moscow; MoscowLeonid I. Dvoretskiy
Sechenov First Moscow State Medical University (Sechenov University)
Email: antimicrob@yandex.ru
ORCID iD: 0000-0003-3186-0102
D. Sci. (Med.), Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation, MoscowVladimir A. Petrov
Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University MEPhI
Email: antimicrob@yandex.ru
ORCID iD: 0000-0002-8580-933X
D. Sci. (Med.), Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University MEPhI
Russian Federation, ObninskReferences
- Ситников И.Г., Фазылов В.Х., Силина Е.В. Лечение гриппа и других ОРВИ у больных сахарным диабетом. Терапевтический архив. 2019;91(10):39-47 [Sitnikov IG, Fazylov VKh, Silina EV. Treatment of influenza and other acute respiratory viral infections in patients with diabetes mellitus. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(10):39-47 (in Russian)]. doi: 10.26442/00403660.2019.10.000333
- Хамитов Р.Ф. Острые респираторные инфекции в амбулаторной практике в эпоху COVID-19: роль и место антибактериальной терапии. РМЖ. Медицинское обозрение. 2020;4(4):214-8 [Khamitov RF. Acute respiratory infections in outpatient care in the era of the COVID-19 pandemic: the role and position of antibacterial therapy. Russian Medical Inquiry. 2020;4(4):214-8 (in Russian)]. doi: 10.32364/2587-6821-2020-4-4-214-218
- Скрябина А.А., Никифоров В.В., Шахмарданов М.З., Застрожин М.С. Бактериальные осложнения гриппа (обзор литературы). Лечащий Врач. 2022;11(25):48-54 [Skryabina AA, Nikiforov VV, Shakhmardanov MZ, Zastrozhin MS. Bacterial complications of influenza (literature review). Lechaschii Vrach. 2022;11(25):48-54 (in Russian)]. doi: 10.51793/OS.2022.25.11.008
- Сборник тезисов докладов четвертой всероссийской конференции «Физика водных растворов». М.: МЕСОЛ, 2021 [Sbornik tezisov dokladov chetvertoi vserossiiskoi konferentsii “Fizika vodnykh rastvorov”. Moscow: MESOL, 2021 (in Russian)].
- Tarasov SA, Gorbunov EA, Don ES, et al. Insights into the mechanism of action of highly diluted biologics. J Immunol. 2020;205(5):1345-54. doi: 10.4049/jimmunol.2000098
- Хамитов Р.Ф., Никифоров В.В., Зайцев А.А., Трагира И.Н. Оценка эффективности и безопасности комплексного противовирусного препарата на основе антител в терапии взрослых больных острой респираторной вирусной инфекцией. Терапевтический архив. 2022;94(1):83-93 [Khamitov RF, Nikiforov VV, Zaytsev AA, Tragira IN. Evaluation of the efficacy and safety of a complex antiviral drug based on antibodies in the treatment of adult patients with acute respiratory viral infection. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(1):83-93 (in Russian)]. doi: 10.26442/00403660.2022.01.201345
- Еженедельный национальный бюллетень по гриппу и ОРВИ за 10–26-ю недели 2022 года. Режим доступа: https://www.influenza.spb.ru/system/epidemic_situation/ Ссылка активна на 07.02.2023 [Weekly national influenza and SARS bulletin for weeks 10–26, 2022. Available at: https://www.influenza.spb.ru/system/epidemic_situation/ Accessed: 07.02.2023 (in Russian)].
- Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID- 19: a systematic review and meta-analysis. J Infect. 2020;81:266-75. doi: 10.1016/j.jinf.2020.05.046
- Uetani K, Hiroi M, Meguro T, et al. Influenza A virus abrogates IFN. Response in respiratory epithelial cells by disruption of the Jak/Stat pathway. Eur J Immunol. 2008;38(6):278-85. doi: 10.1002/eji.200737045